London, England, United Kingdom In 2012 was created Pavillion Capital, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.
Among the most popular fund investment industries, there are B2B, Procurement. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Ascletis, Tradeshift, Yodo1.
The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2014. This Pavillion Capital works on 9 percentage points less the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2018. The average startup value when the investment from Pavillion Capital is 100-500 millions dollars. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The overall number of key employees were 1.
The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Pavillion Capital, startups are often financed by Notion, Lightspeed Venture Partners, Infinity Ventures. The meaningful sponsors for the fund in investment in the same round are Tasly Pharmaceutical, Singtel Innov8, Sequoia Capital. In the next rounds fund is usually obtained by Santander InnoVentures, DCM Ventures, e.ventures.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 3dot6 Ventures | - |
| Alphachain | Puerto Rico, San Juan, United States |
| Cantor Fitzgerald | New York, New York, United States |
| Cavallo Consulting | California, Corona, United States |
| Celanese | Irving, Texas, United States |
| Clal Insurance Enterprises Holdings | Israel, Kiryat Gat, South District |
| DNB | Norway, Oslo |
| Future Positive Capital | France, Ile-de-France, Paris |
| Halyard Capital | New York, New York, United States |
| Hull Street Capital | Bethesda, Maryland, United States |
| Intel | California, Santa Clara, United States |
| LG Uplus | Seoul, Seoul-t'ukpyolsi, South Korea |
| Montage Ventures | California, Menlo Park, United States |
| Mount Nathan Advisors | Central, Central Region, Singapore |
| O.R.Technologies | - |
| Rose-Hulman Ventures | Indiana, Terre Haute, United States |
| SODICAL | Castilla y Leon, Spain, Valladolid |
| Trainocate Japan | Japan, Tokyo |
| Warby Parker | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Circle Pharma | $66M | 16 Jun 2021 | San Francisco, California, United States | ||
Zilliz | $43M | 16 Nov 2020 | Shanghai, China | ||
Ascletis | $35M | 02 Sep 2015 | North Carolina, United States | ||
freee | $6M | 25 Sep 2014 | Chiyoda, Japan | ||
| $60M | 23 Jul 2014 | Dongcheng District, Beijing, China | |||
Yodo1 | $11M | 10 Dec 2013 | China, Beijing |
– Circle Pharma from South San Francisco develops macrocycle drug discovery and development company focused on intractable cancer targets.
– The company raised $66m in Series C financing.
– The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company.
– The new investment will be used to advance its wholly owned cyclin-targeted programs towards the clinic.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Circle Pharma | $66M | 16 Jun 2021 | San Francisco, California, United States | ||
Zilliz | $43M | 16 Nov 2020 | Shanghai, China | ||
Ascletis | $35M | 02 Sep 2015 | North Carolina, United States | ||
freee | $6M | 25 Sep 2014 | Chiyoda, Japan | ||
| $60M | 23 Jul 2014 | Dongcheng District, Beijing, China | |||
Yodo1 | $11M | 10 Dec 2013 | China, Beijing |
